Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation - Summary - MDSpire
Advertisement
Tildrakizumab Enhances Disease Management and Patient-Reported Outcomes in Individuals with Moderate-to-Severe Chronic Plaque Psoriasis: Findings from a Prospective Real-World Investigation
To investigate the impact of tildrakizumab treatment on specific patient-reported outcomes (PROMs) in real-world clinical practice and the correlation between improvements in PASI and quality of life over time.
Key Findings:
Tildrakizumab induced rapid and sustained improvements in skin clearance and multiple patient-reported domains, including quality of life, pruritus, and sleep.
Significant correlation between PASI and PROMs was strongest during early treatment and attenuated over time, highlighting the need for comprehensive assessment.
Findings support the integration of PROMs into long-term psoriasis management to better capture patient-centered outcomes.
Interpretation:
The study highlights the importance of considering patient-reported outcomes alongside clinical severity scores to fully understand the impact of psoriasis treatment on patients' lives.
Limitations:
Small sample size with only 33 patients enrolled, which may limit generalizability.
Limited follow-up data with only 17 patients completing PROMs at week 52, potentially introducing bias.
Conclusion:
Tildrakizumab shows promise in improving both clinical and patient-centered outcomes in psoriasis, emphasizing the need for comprehensive assessment in treatment evaluation.
